Tranexamic Acid for Total Knee Arthroscopy

• Status: Active, not recruiting
• Trial end date: 2021-05-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this investigation is to determine the most effective regimen of administration of tranexamic acid to improve clinical outcome among patients undergoing total knee arthroplasty.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Miriam Hospital
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria:

• Adult patients who are scheduled to undergo total knee arthroplasty will be approached to participate.

Exclusion Criteria:

• Known allergy to TXA

• History of venous or arterial thrombosis within 12 months

• History of thromboembolic event within 12 months

• Acute ischemic event (stroke, transient ischemic attack, myocardial infarction, ischemic retinopathy) within 6 months

• Known congenital thrombophilia

Relative Contraindications:

• History of seizures

• Impaired kidney function (Glomerular filtration rate < 30 ml/min)